{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:35:43Z","timestamp":1791516943129,"version":"4.3.4"},"reference-count":58,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single-day production of nonactivated CAR T cells engineered to secrete interleukin-18 (IL-18), a proinflammatory cytokine that enhances T-cell function. These nonactivated CART19-IL-18 cells (IL-18\u2013secreting anti-CD19 CAR T cells) exhibit robust antitumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of na\u00efve-like nonactivated CAR T cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of \u03b1-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18\u2013enhanced, activation-free CAR T-cell product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T-cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033460","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:37:35Z","timestamp":1776368255000},"page":"710-723","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Single-day nonactivated IL-18\u2013armed CAR T cells establish a durable, stemlike state with enhanced persistence"],"prefix":"10.1182","volume":"148","author":[{"given":"Joseph S.","family":"Durgin","sequence":"first","affiliation":[{"name":"1Department of Dermatology, University of Michigan, Ann Arbor, MI"},{"name":"2Department of Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7378-8379","authenticated-orcid":false,"given":"Shin","family":"Seo","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Department of Bioengineering, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-0624","authenticated-orcid":false,"given":"Shadab","family":"Kazmi","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5253-0010","authenticated-orcid":false,"given":"Bakir","family":"Valentic","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-4099","authenticated-orcid":false,"given":"Chloe","family":"Leff","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1246-7307","authenticated-orcid":false,"given":"Martina","family":"Markovska","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Jin","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Berjis","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandana","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0675-9734","authenticated-orcid":false,"given":"Ashwin","family":"Sannecy","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5943","authenticated-orcid":false,"given":"Gabriela","family":"Plesa","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1284-1268","authenticated-orcid":false,"given":"Khatuna","family":"Gabunia","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9725-6277","authenticated-orcid":false,"given":"John","family":"Scholler","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"6Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-4544","authenticated-orcid":false,"given":"Roddy S.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Ghassemi","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2026080611222985500_bib1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1080\/10428194.2021.1913146","article-title":"CAR-T cell persistence in the treatment of leukemia and lymphoma","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2026080611222985500_bib2","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2026080611222985500_bib3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2026080611222985500_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139605","article-title":"CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering [abstract]","volume":"136","author":"Majzner","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026080611222985500_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus\u2013driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2026080611222985500_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"2026080611222985500_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ymthe.2021.11.014","article-title":"Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase","volume":"30","author":"Durgin","year":"2022","journal-title":"Mol Ther"},{"issue":"11","key":"2026080611222985500_bib8","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"issue":"13","key":"2026080611222985500_bib9","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"1","key":"2026080611222985500_bib10","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1096\/fj.201901809R","article-title":"IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells","volume":"34","author":"Huang","year":"2020","journal-title":"FASEB J"},{"issue":"22","key":"2026080611222985500_bib11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood.V128.22.816.816","article-title":"IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning","volume":"128","author":"Avanzi","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2026080611222985500_bib12","doi-asserted-by":"crossref","first-page":"e166028","DOI":"10.1172\/JCI166028","article-title":"IL-18\u2013secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"issue":"18","key":"2026080611222985500_bib13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"2026080611222985500_bib14","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/bloodadvances.2023012240","article-title":"\u201cDon't keep me waiting\u201d: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes","volume":"8","author":"Vadgama","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026080611222985500_bib15","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2026080611222985500_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"8","key":"2026080611222985500_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"27","key":"2026080611222985500_bib18","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026080611222985500_bib19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.4049\/jimmunol.1102757","article-title":"Substrate rigidity regulates human T cell activation and proliferation","volume":"189","author":"O\u2019Connor","year":"2012","journal-title":"J Immunol"},{"key":"2026080611222985500_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"issue":"1","key":"2026080611222985500_bib21","doi-asserted-by":"crossref","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","article-title":"GSEApy: a comprehensive package for performing gene set enrichment analysis in Python","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"key":"2026080611222985500_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.omtm.2020.07.008","article-title":"Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design","volume":"18","author":"Ghassemi","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2026080611222985500_bib23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"issue":"6735","key":"2026080611222985500_bib24","doi-asserted-by":"crossref","first-page":"eadn2337","DOI":"10.1126\/science.adn2337","article-title":"KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection","volume":"387","author":"Fagerberg","year":"2025","journal-title":"Science"},{"key":"2026080611222985500_bib25","doi-asserted-by":"crossref","first-page":"1022808","DOI":"10.3389\/fimmu.2022.1022808","article-title":"IL-7: a promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"2026080611222985500_bib26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/cdd.2013.25","article-title":"Mcl-1 antagonizes Bax\/Bak to promote effector CD4(+) and CD8(+) T-cell responses","volume":"20","author":"Tripathi","year":"2013","journal-title":"Cell Death Differ"},{"issue":"49","key":"2026080611222985500_bib27","doi-asserted-by":"crossref","first-page":"eaba7918","DOI":"10.1126\/sciimmunol.aba7918","article-title":"TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells","volume":"5","author":"Sekine","year":"2020","journal-title":"Sci Immunol"},{"issue":"7620","key":"2026080611222985500_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"issue":"18","key":"2026080611222985500_bib29","doi-asserted-by":"crossref","first-page":"12112","DOI":"10.1128\/JVI.79.18.12112-12116.2005","article-title":"Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation","volume":"79","author":"Thimme","year":"2005","journal-title":"J Virol"},{"key":"2026080611222985500_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-981-32-9717-3_3","article-title":"The TNF\u2013TNFR family of co-signal molecules","volume":"1189","author":"So","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2026080611222985500_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.coviro.2016.12.001","article-title":"The role of CD27 in anti-viral T-cell immunity","volume":"22","author":"Grant","year":"2017","journal-title":"Curr Opin Virol"},{"issue":"9","key":"2026080611222985500_bib32","doi-asserted-by":"crossref","first-page":"113043","DOI":"10.1016\/j.celrep.2023.113043","article-title":"The malate-aspartate shuttle is important for de novo serine biosynthesis","volume":"42","author":"Broeks","year":"2023","journal-title":"Cell Rep"},{"key":"2026080611222985500_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2015.078","article-title":"Alpha-ketoglutarate: physiological functions and applications","volume":"24","author":"Wu","year":"2016","journal-title":"Biomol Ther"},{"issue":"6374","key":"2026080611222985500_bib34","doi-asserted-by":"crossref","first-page":"eaan2788","DOI":"10.1126\/science.aan2788","article-title":"Spermidine in health and disease","volume":"359","author":"Madeo","year":"2018","journal-title":"Science"},{"issue":"8","key":"2026080611222985500_bib35","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.freeradbiomed.2006.07.008","article-title":"Free radical scavenging action of the natural polyamine spermine in rat liver mitochondria","volume":"41","author":"Sava","year":"2006","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2026080611222985500_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"Van der Windt","year":"2012","journal-title":"Immunity"},{"issue":"8","key":"2026080611222985500_bib37","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026080611222985500_bib38","doi-asserted-by":"crossref","first-page":"e2218345120","DOI":"10.1073\/pnas.2218345120","article-title":"Thioredoxin-interacting protein is essential for memory T cell formation via the regulation of the redox metabolism","volume":"120","author":"Kokubo","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026080611222985500_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/eji.202048851","article-title":"The thioredoxin-1 inhibitor Txnip restrains effector T-cell and germinal center B-cell expansion","volume":"51","author":"Muri","year":"2021","journal-title":"Eur J Immunol"},{"issue":"30","key":"2026080611222985500_bib40","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1073\/pnas.1406259111","article-title":"The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells","volume":"111","author":"Giordano","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026080611222985500_bib41","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/15548627.2015.1055439","article-title":"TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy","volume":"11","author":"Matsuzawa","year":"2015","journal-title":"Autophagy"},{"issue":"9","key":"2026080611222985500_bib42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-019-0566-4","article-title":"Stress\u2013glucocorticoid\u2013TSC22D3 axis compromises therapy-induced antitumor immunity","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med"},{"key":"2026080611222985500_bib43","doi-asserted-by":"crossref","first-page":"611038","DOI":"10.3389\/fonc.2021.611038","article-title":"CHI3L2 is a novel prognostic biomarker and correlated with immune infiltrates in gliomas","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"2026080611222985500_bib44","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"2026080611222985500_bib45","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2018-99-115351","article-title":"Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes [abstract]","volume":"132","author":"Kotani","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026080611222985500_bib46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2026080611222985500_bib47","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"7","key":"2026080611222985500_bib48","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2026080611222985500_bib49","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2026080611222985500_bib50","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4049\/jimmunol.170.2.1084","article-title":"Chemoattraction of human T cells by IL-18","volume":"170","author":"Komai-Koma","year":"2003","journal-title":"J Immunol"},{"issue":"7817","key":"2026080611222985500_bib51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"1","key":"2026080611222985500_bib52","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1038\/s41598-018-24676-6","article-title":"The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations","volume":"8","author":"O\u2019Connor","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"2026080611222985500_bib53","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang","year":"2015","journal-title":"J Clin Invest"},{"issue":"13","key":"2026080611222985500_bib54","doi-asserted-by":"crossref","first-page":"e2319429121","DOI":"10.1073\/pnas.2319429121","article-title":"Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer","volume":"121","author":"Han","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026080611222985500_bib55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"issue":"3","key":"2026080611222985500_bib56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"7621","key":"2026080611222985500_bib57","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"issue":"2","key":"2026080611222985500_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/710\/2536607\/blood_bld-2026-033460-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/710\/2536607\/blood_bld-2026-033460-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:22:59Z","timestamp":1786029779000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/6\/710\/567808\/Single-day-nonactivated-IL-18-armed-CAR-T-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033460","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,6]]},"published":{"date-parts":[[2026,8,6]]}}}